PEPTIDE COMPARISON

PT-141 vs Melanotan II

An FDA-reviewed bremelanotide product compared with an unapproved melanocortin analog.

QUICK ANSWER

PT-141 vs Melanotan II: the main difference.

The shared melanocortin family does not make these products comparable in status or evidence. Vyleesi has one narrow FDA-approved use; Melanotan II has no approved use and a safety-concern-heavy human record.

Decision field	PT-141 / Bremelanotide	Melanotan II
Human research	Two randomized phase 3 trials for a narrow population	Case reports and uncontrolled use
FDA status	Vyleesi approved for one specific HSDD indication	Not approved; illegal-marketing and safety concerns
Primary use studied	Acquired, generalized HSDD in premenopausal women	No approved tanning or sexual-health use
Product boundary	Approval attaches to branded formulation and label	Unapproved products may have quality uncertainty
Evidence confidence	High only for the labeled use	Very low

SOURCES

PT-141 vs Melanotan II sources.

FDA / 2019Vyleesi prescribing informationU.S. FDA Human trial / 2019Bremelanotide for HSDD: two randomized phase 3 trialsPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Case report / 2020Renal infarction associated with Melanotan II usePubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA FDA / 2007FDA report on illegally marketed Melanotan productsU.S. FDA

PT-141 vs Melanotan II: the main difference.

PT-141 vs Melanotan II sources.

Questions related to PT-141 vs Melanotan II.